Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT01681095

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Marc Sakwa, MD (from the registry)
Registry
  • NCT NCT01681095
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01681095. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2017-03-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
Condition
Myocardial Ischemia
Condition
Coronary Disease
Condition
Heart Diseases
Condition
Valvular Heart Disease
Intervention (Drug)
Custodiol HTK
Intervention (Drug)
Cold Blood Cardioplegia
Lead sponsor
Marc Sakwa, MD (class: other)
Collaborator
Essential Pharmaceuticals, LLC (class: other)

Record details

Record id
cardio:ct-nct01681095
Content hash
039921d7631cd23ce9377b9206010e9f66bec0780e9c8fd02cd66f475c2bc443